J-u Blohmer
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).
Journal: ESMO open
Published: June 18, 2025
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 20, 2022
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 18, 2022
Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers.
Journal: Journal of cancer research and clinical oncology
Published: December 17, 2021
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 27, 2020
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 24, 2020
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 17, 2019
Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
Journal: Breast (Edinburgh, Scotland)
Published: September 19, 2017
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 11, 2016
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).
Journal: Geburtshilfe und Frauenheilkunde
Published: May 02, 2015
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 17, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026